FIELD: chemistry; pharmaceutics.
SUBSTANCE: present invention relates to novel pharmaceutical dosage forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide, in particular to its ditosylate form.
EFFECT: dosage form provides highly reproducible profile of disintegration and dissolution in aqueous solutions and, therefore, is suitable for oral administration.
18 cl, 1 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| VARIOUS FORMS OF 6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDIN-1-YL)BENZYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE | 2019 |
|
RU2826176C2 |
| PHARMACEUTICAL COMPOSITION BASED ON N-BENZYL-N-METHYL-1-PHENYLPYRROLO [1,2-A] PYRAZINE-3-CARBOXAMIDE | 2017 |
|
RU2689396C2 |
| PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
| PHARMACEUTICAL PREPARATION | 2020 |
|
RU2822063C2 |
| TABLETS PREPARATION TECHNOLOGY FOR CGRP-ACTIVE COMPOUNDS | 2015 |
|
RU2696578C1 |
| PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN LOBEGLITAZONE FOR ORAL ADMINISTRATION | 2015 |
|
RU2709526C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING N-[(1-BUTYL-4-PIPERIDINYL) METHYL]-3,4-DIHYDRO-2N-[1,3]OXAZINO[3,2-a]INDOLE-10- CARBOXAMIDE OR ITS SALT, AND RELATED PRODUCTION METHOD INCLUDING AIR-STREAM GRANULATION | 2003 |
|
RU2329789C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING JANUS KINASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2744432C2 |
| IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2465900C2 |
